WS19-3 Microbiota profiling during 1-year of clinical stability in people with cystic fibrosis - CFMATTERS Consortium

Gisli Einarsson, Evelyn Flanagan, Andrew Lee, Clodagh McGettigan, Ciaran Smith, Deirdre Gilpin, Joseph Elborn, Barry J. Plant, Michael Tunney, on behalf of the CFMATTERS consortium

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Objectives: The aim of this study was to longitudinally determine microbial community composition during clinical stability in people with cystic fibrosis (PWCF) who did not experience pulmonary exacerbation (PEx) over a period of one year.
Methods: Sputum samples (n=95) were collected from PWCF (n=19) enrolled to the CFMATTERS study (Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified) at baseline (day 0) and subsequently at three monthly intervals for up-to 12 months (month 3, month 6, month 9 and month 12) in absence of PEx. Genomic DNA was extracted and microbial community profiles determined by sequencing the 16S rRNA marker gene using the Illumina MiSeq platform. Microbial community composition was determined as relative abundance (RA) of the corresponding taxa and alpha-diversity (taxonomic richness, Shannon-Wiener diversity, evenness and dominance) was calculated for each sample.
Results: Over a period of one year, there was no significant differences in lung function (FEV1 % of predicted [p=0.997] and FVC % of predicted [p=0.977], respectively) during clinical stability. Some intra-patient variability was observed between visits; however, overall community composition remained stable. No difference was observed in RA for the main aerobic taxa (Pseudomonas spp. [p=0.857]; Streptococcus spp. [p=0.888], Staphylococcus spp. [p=0.918]) and obligate anaerobic taxa (Prevotella spp. [p=0.977]; Veillonella spp. [p=0.314]; Porphyromonas spp. [p=0.513]). Similarly, there was no difference observed for the main ecological measurements of community richness (p=0.835), Shannon-Wiener diversity (p=0.974), evenness (p=0.722) and dominance (p=0.987).
Conclusion: Despite some intra-patient variability, during periods of clinical stability, microbial community composition remains stable. Similarly, alpha-diversity measurements show little change over time.
Funding: CFMATTERS (603038.)
Original languageEnglish
Title of host publicationJournal of Cysric Fibrosis
PublisherEuropean Cystic Fibrosis Society
PagesS35
Number of pages1
VolumeVolume 18
Edition Supplement 1
DOIs
Publication statusPublished - 06 Jun 2019
Event 42nd CF Conference. 05-08 June 2019, Liverpool, United Kingdom - Liverpool, United Kingdom
Duration: 05 Jun 201908 Jun 2019
Conference number: 42nd
https://www.ecfs.eu/liverpool2019

Conference

Conference 42nd CF Conference. 05-08 June 2019, Liverpool, United Kingdom
CountryUnited Kingdom
CityLiverpool
Period05/06/201908/06/2019
Internet address

Fingerprint

Microbiota
Cystic Fibrosis
Lung
Porphyromonas
Veillonella
Prevotella
Biota
Pseudomonas
Streptococcus
Sputum
Staphylococcus
rRNA Genes
Anti-Bacterial Agents
DNA
Therapeutics

Cite this

Einarsson, G., Flanagan, E., Lee, A., McGettigan, C., Smith, C., Gilpin, D., ... on behalf of the CFMATTERS consortium (2019). WS19-3 Microbiota profiling during 1-year of clinical stability in people with cystic fibrosis - CFMATTERS Consortium. In Journal of Cysric Fibrosis ( Supplement 1 ed., Vol. Volume 18, pp. S35). European Cystic Fibrosis Society. https://doi.org/10.1016/S1569-1993(19)30230-9
Einarsson, Gisli ; Flanagan, Evelyn ; Lee, Andrew ; McGettigan, Clodagh ; Smith, Ciaran ; Gilpin, Deirdre ; Elborn, Joseph ; Plant, Barry J. ; Tunney, Michael ; on behalf of the CFMATTERS consortium. / WS19-3 Microbiota profiling during 1-year of clinical stability in people with cystic fibrosis - CFMATTERS Consortium. Journal of Cysric Fibrosis. Vol. Volume 18 Supplement 1. ed. European Cystic Fibrosis Society, 2019. pp. S35
@inproceedings{fac40058bcfa4ac6b4ac5367cc6a9e9f,
title = "WS19-3 Microbiota profiling during 1-year of clinical stability in people with cystic fibrosis - CFMATTERS Consortium",
abstract = "Objectives: The aim of this study was to longitudinally determine microbial community composition during clinical stability in people with cystic fibrosis (PWCF) who did not experience pulmonary exacerbation (PEx) over a period of one year.Methods: Sputum samples (n=95) were collected from PWCF (n=19) enrolled to the CFMATTERS study (Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified) at baseline (day 0) and subsequently at three monthly intervals for up-to 12 months (month 3, month 6, month 9 and month 12) in absence of PEx. Genomic DNA was extracted and microbial community profiles determined by sequencing the 16S rRNA marker gene using the Illumina MiSeq platform. Microbial community composition was determined as relative abundance (RA) of the corresponding taxa and alpha-diversity (taxonomic richness, Shannon-Wiener diversity, evenness and dominance) was calculated for each sample. Results: Over a period of one year, there was no significant differences in lung function (FEV1 {\%} of predicted [p=0.997] and FVC {\%} of predicted [p=0.977], respectively) during clinical stability. Some intra-patient variability was observed between visits; however, overall community composition remained stable. No difference was observed in RA for the main aerobic taxa (Pseudomonas spp. [p=0.857]; Streptococcus spp. [p=0.888], Staphylococcus spp. [p=0.918]) and obligate anaerobic taxa (Prevotella spp. [p=0.977]; Veillonella spp. [p=0.314]; Porphyromonas spp. [p=0.513]). Similarly, there was no difference observed for the main ecological measurements of community richness (p=0.835), Shannon-Wiener diversity (p=0.974), evenness (p=0.722) and dominance (p=0.987). Conclusion: Despite some intra-patient variability, during periods of clinical stability, microbial community composition remains stable. Similarly, alpha-diversity measurements show little change over time.Funding: CFMATTERS (603038.)",
author = "Gisli Einarsson and Evelyn Flanagan and Andrew Lee and Clodagh McGettigan and Ciaran Smith and Deirdre Gilpin and Joseph Elborn and Plant, {Barry J.} and Michael Tunney and {on behalf of the CFMATTERS consortium}",
year = "2019",
month = "6",
day = "6",
doi = "https://doi.org/10.1016/S1569-1993(19)30230-9",
language = "English",
volume = "Volume 18",
pages = "S35",
booktitle = "Journal of Cysric Fibrosis",
publisher = "European Cystic Fibrosis Society",
edition = "Supplement 1",

}

Einarsson, G, Flanagan, E, Lee, A, McGettigan, C, Smith, C, Gilpin, D, Elborn, J, Plant, BJ, Tunney, M & on behalf of the CFMATTERS consortium 2019, WS19-3 Microbiota profiling during 1-year of clinical stability in people with cystic fibrosis - CFMATTERS Consortium. in Journal of Cysric Fibrosis. Supplement 1 edn, vol. Volume 18, European Cystic Fibrosis Society, pp. S35, 42nd CF Conference. 05-08 June 2019, Liverpool, United Kingdom, Liverpool, United Kingdom, 05/06/2019. https://doi.org/10.1016/S1569-1993(19)30230-9

WS19-3 Microbiota profiling during 1-year of clinical stability in people with cystic fibrosis - CFMATTERS Consortium. / Einarsson, Gisli; Flanagan, Evelyn; Lee, Andrew; McGettigan, Clodagh; Smith, Ciaran; Gilpin, Deirdre; Elborn, Joseph; Plant, Barry J.; Tunney, Michael; on behalf of the CFMATTERS consortium.

Journal of Cysric Fibrosis. Vol. Volume 18 Supplement 1. ed. European Cystic Fibrosis Society, 2019. p. S35.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - WS19-3 Microbiota profiling during 1-year of clinical stability in people with cystic fibrosis - CFMATTERS Consortium

AU - Einarsson, Gisli

AU - Flanagan, Evelyn

AU - Lee, Andrew

AU - McGettigan, Clodagh

AU - Smith, Ciaran

AU - Gilpin, Deirdre

AU - Elborn, Joseph

AU - Plant, Barry J.

AU - Tunney, Michael

AU - on behalf of the CFMATTERS consortium

PY - 2019/6/6

Y1 - 2019/6/6

N2 - Objectives: The aim of this study was to longitudinally determine microbial community composition during clinical stability in people with cystic fibrosis (PWCF) who did not experience pulmonary exacerbation (PEx) over a period of one year.Methods: Sputum samples (n=95) were collected from PWCF (n=19) enrolled to the CFMATTERS study (Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified) at baseline (day 0) and subsequently at three monthly intervals for up-to 12 months (month 3, month 6, month 9 and month 12) in absence of PEx. Genomic DNA was extracted and microbial community profiles determined by sequencing the 16S rRNA marker gene using the Illumina MiSeq platform. Microbial community composition was determined as relative abundance (RA) of the corresponding taxa and alpha-diversity (taxonomic richness, Shannon-Wiener diversity, evenness and dominance) was calculated for each sample. Results: Over a period of one year, there was no significant differences in lung function (FEV1 % of predicted [p=0.997] and FVC % of predicted [p=0.977], respectively) during clinical stability. Some intra-patient variability was observed between visits; however, overall community composition remained stable. No difference was observed in RA for the main aerobic taxa (Pseudomonas spp. [p=0.857]; Streptococcus spp. [p=0.888], Staphylococcus spp. [p=0.918]) and obligate anaerobic taxa (Prevotella spp. [p=0.977]; Veillonella spp. [p=0.314]; Porphyromonas spp. [p=0.513]). Similarly, there was no difference observed for the main ecological measurements of community richness (p=0.835), Shannon-Wiener diversity (p=0.974), evenness (p=0.722) and dominance (p=0.987). Conclusion: Despite some intra-patient variability, during periods of clinical stability, microbial community composition remains stable. Similarly, alpha-diversity measurements show little change over time.Funding: CFMATTERS (603038.)

AB - Objectives: The aim of this study was to longitudinally determine microbial community composition during clinical stability in people with cystic fibrosis (PWCF) who did not experience pulmonary exacerbation (PEx) over a period of one year.Methods: Sputum samples (n=95) were collected from PWCF (n=19) enrolled to the CFMATTERS study (Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified) at baseline (day 0) and subsequently at three monthly intervals for up-to 12 months (month 3, month 6, month 9 and month 12) in absence of PEx. Genomic DNA was extracted and microbial community profiles determined by sequencing the 16S rRNA marker gene using the Illumina MiSeq platform. Microbial community composition was determined as relative abundance (RA) of the corresponding taxa and alpha-diversity (taxonomic richness, Shannon-Wiener diversity, evenness and dominance) was calculated for each sample. Results: Over a period of one year, there was no significant differences in lung function (FEV1 % of predicted [p=0.997] and FVC % of predicted [p=0.977], respectively) during clinical stability. Some intra-patient variability was observed between visits; however, overall community composition remained stable. No difference was observed in RA for the main aerobic taxa (Pseudomonas spp. [p=0.857]; Streptococcus spp. [p=0.888], Staphylococcus spp. [p=0.918]) and obligate anaerobic taxa (Prevotella spp. [p=0.977]; Veillonella spp. [p=0.314]; Porphyromonas spp. [p=0.513]). Similarly, there was no difference observed for the main ecological measurements of community richness (p=0.835), Shannon-Wiener diversity (p=0.974), evenness (p=0.722) and dominance (p=0.987). Conclusion: Despite some intra-patient variability, during periods of clinical stability, microbial community composition remains stable. Similarly, alpha-diversity measurements show little change over time.Funding: CFMATTERS (603038.)

U2 - https://doi.org/10.1016/S1569-1993(19)30230-9

DO - https://doi.org/10.1016/S1569-1993(19)30230-9

M3 - Conference contribution

VL - Volume 18

SP - S35

BT - Journal of Cysric Fibrosis

PB - European Cystic Fibrosis Society

ER -

Einarsson G, Flanagan E, Lee A, McGettigan C, Smith C, Gilpin D et al. WS19-3 Microbiota profiling during 1-year of clinical stability in people with cystic fibrosis - CFMATTERS Consortium. In Journal of Cysric Fibrosis. Supplement 1 ed. Vol. Volume 18. European Cystic Fibrosis Society. 2019. p. S35 https://doi.org/10.1016/S1569-1993(19)30230-9